Novartis AG ADR
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $14,279,667 | $13,620,000 | $13,558,000 | $13,172,000 |
Gross Profit | 11,514 | 10,393,000 | 10,234,000 | 9,938,000 |
EBITDA | 4,873 | 5,831,000 | 5,188,000 | 5,614,000 |
EBIT | 4,677,000 | 3,560,000 | 3,649,000 | |
Net Income | 4,024 | 3,606,000 | 2,818,000 | 3,189,000 |
Net Change In Cash | 14,279,667 | 13,620,000 | 13,558,000 | 13,172,000 |
Free Cash Flow | 6,106,000 | 2,151,000 | 3,062,000 | 5,487,000 |
Cash | 6,656,000 | 7,066,000 | 11,459,000 | 13,609,000 |
Basic Shares | 1,960,000 | 1,979,000 | 2,004,000 | 2,027,000 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $51,722,000 | $46,660,000 | $51,828,000 | $52,877,000 |
Gross Profit | 38,895,000 | 34,188,000 | 36,342,000 | 37,010,000 |
EBITDA | 20,715,000 | 18,286,000 | 14,726,000 | 17,132,000 |
EBIT | 14,646,000 | 10,009,000 | 8,021,000 | 11,703,000 |
Net Income | 11,941,000 | 14,850,000 | 6,955,000 | 24,021,000 |
Net Change In Cash | 51,722,000 | 46,660,000 | 51,828,000 | 52,877,000 |
Free Cash Flow | 13,805,000 | 11,705,000 | 11,565,000 | 12,100,000 |
Cash | 11,459,000 | 13,393,000 | 7,517,000 | 12,407,000 |
Basic Shares | 2,035,000 | 2,092,000 | 2,197,000 | 2,260,000 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | $2.42 |
2025-03-31 | $2.28 |
2024-12-31 | $1.98 |
2024-09-30 | $2.06 |
